Literature DB >> 23142604

Gastrointestinal complications of cystic fibrosis.

Daniel Gelfond1, Drucy Borowitz.   

Abstract

The cystic fibrosis transmembrane regulator protein (CFTR) is an ion channel in the apical surface of epithelial membranes that regulates other ion channels. Dysfunction of CFTR leads to the clinical entity of CF when mutations in CFTR are inherited in an autosomal recessive fashion. Although airway obstruction, inflammation, and infection are usually the most serious consequences of CFTR dysfunction because they lead to respiratory failure, CFTR dysfunction affects the intestinal tract and the pancreatic and hepatobiliary ducts in a similar fashion, leading to significant morbidity. This review outlines pathophysiology and common gastrointestinal ailments in the CF population along with current medical and surgical management.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23142604     DOI: 10.1016/j.cgh.2012.11.006

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  21 in total

1.  CFTR is a tumor suppressor gene in murine and human intestinal cancer.

Authors:  B L N Than; J F Linnekamp; T K Starr; D A Largaespada; A Rod; Y Zhang; V Bruner; J Abrahante; A Schumann; T Luczak; A Niemczyk; M G O'Sullivan; J P Medema; R J A Fijneman; G A Meijer; E Van den Broek; C A Hodges; P M Scott; L Vermeulen; R T Cormier
Journal:  Oncogene       Date:  2016-01-11       Impact factor: 9.867

Review 2.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

Review 3.  Endoglin in liver fibrogenesis: Bridging basic science and clinical practice.

Authors:  Steffen K Meurer; Muhammad Alsamman; David Scholten; Ralf Weiskirchen
Journal:  World J Biol Chem       Date:  2014-05-26

4.  Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.

Authors:  Steven M Rowe; Sonya L Heltshe; Tanja Gonska; Scott H Donaldson; Drucy Borowitz; Daniel Gelfond; Scott D Sagel; Umer Khan; Nicole Mayer-Hamblett; Jill M Van Dalfsen; Elizabeth Joseloff; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2014-07-15       Impact factor: 21.405

Review 5.  Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.

Authors:  Misak Harutyunyan; Yunjie Huang; Kyu-Shik Mun; Fanmuyi Yang; Kavisha Arora; Anjaparavanda P Naren
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-12-14       Impact factor: 5.464

6.  Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis.

Authors:  Wen Ye; Michael R Narkewicz; Daniel H Leung; Wikrom Karnsakul; Karen F Murray; Estella M Alonso; John C Magee; Sarah Jane Schwarzenberg; Alexander Weymann; Jean P Molleston
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-01       Impact factor: 2.839

7.  Defining a mutational panel and predicting the prevalence of cystic fibrosis in oman.

Authors:  Uwe W Fass; Majid Al-Salmani; Said Bendahhou; Ganji Shivalingam; Catherine Norrish; Kallesh Hebal; Fiona Clark; Thomas Heming; Saleh Al-Khusaiby
Journal:  Sultan Qaboos Univ Med J       Date:  2014-07-24

8.  Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs.

Authors:  David A Stoltz; Tatiana Rokhlina; Sarah E Ernst; Alejandro A Pezzulo; Lynda S Ostedgaard; Philip H Karp; Melissa S Samuel; Leah R Reznikov; Michael V Rector; Nicholas D Gansemer; Drake C Bouzek; Mahmoud H Abou Alaiwa; Mark J Hoegger; Paula S Ludwig; Peter J Taft; Tanner J Wallen; Christine Wohlford-Lenane; James D McMenimen; Jeng-Haur Chen; Katrina L Bogan; Ryan J Adam; Emma E Hornick; George A Nelson; Eric A Hoffman; Eugene H Chang; Joseph Zabner; Paul B McCray; Randall S Prather; David K Meyerholz; Michael J Welsh
Journal:  J Clin Invest       Date:  2013-05-08       Impact factor: 14.808

9.  Decreased Wait Time and Increased Satisfaction With Bedside Pancreatic Enzyme Dosing for the Inpatient Adolescent With Cystic Fibrosis: A Quality Improvement Project Comparing Enzyme Self-Administration to Nurse Administration.

Authors:  Brandi Middour-Oxler; Margaret Gettis; Betsy Dye
Journal:  J Patient Exp       Date:  2021-01-12

10.  Changes in fecal microbiota with CFTR modulator therapy: A pilot study.

Authors:  C E Pope; A T Vo; H S Hayden; E J Weiss; S Durfey; S McNamara; A Ratjen; B Grogan; S Carter; L Nay; M R Parsek; P K Singh; E F McKone; M L Aitken; M R Rosenfeld; L R Hoffman
Journal:  J Cyst Fibros       Date:  2020-12-31       Impact factor: 5.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.